24 completed, 13 recruiting, 10 unknown, 2 enrolling by invitation. 28 Not applicable, 6 Phase 2, 4 Phase 3, 4 Phase 4, 2 Phase 1.
Follow MDD: new trials by email Literature Review of MDD trials Research Report on MDD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Individualized fMRI-guided TMS for Depression Active Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Transcranial Magnetic Stimulation (TMS) - Depression, Major Depressive Disorder (MDD) | Early Phase 1 | Not yet recruiting | University of Pennsylvania | 60 | 2026-09-15 | 2026-09-09 |
| Inhaled DMT for Major Depressive Disorder N,N-Dimethyltryptamine (15 mg + 60 mg), N,N-Dimethyltryptamine (1 mg + 4 mg) - MDD, Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Universidade Federal do Rio Grande do Norte | 140 | 2026-08-01 | 2026-07-13 |
| tDCS: Sleep to Mood in Depression (S2M-D) transcranial direct current stimulation (tDCS) - Major Depressive Disorder, MDD | Not applicable | Recruiting | NYU Langone Health | 35 | 2026-06-04 | 2026-06-08 |
| Functional Electrical Stimulation for MDD Functional Electrical Stimulation (FES) - MDD | Not applicable | Not yet recruiting | Unity Health Toronto | 60 | 2026-05-25 | 2026-06-08 |
| Dynamic Network Response to TMS Treatment MDD | Recruiting | Goethe University | 100 | 2025-11-24 | 2026-02-20 | |
| Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD) 60Hz Intermittent Light Therapy, Sham Light Therapy - Depression, MDD | Not applicable | Recruiting | NYU Langone Health | 40 | 2025-08-18 | 2026-06-29 |
| Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in the Treatment of MDD LV232 40mg, LV232 60mg, Escitalopram - MDD | Phase 2 | Recruiting | Vigonvita Life Sciences | 400 | 2025-04-03 | 2026-10-20 |
| NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status Eicosapentaenoic acid (omega-3 fatty acid), Placebo - Obese Adults, MDD | Not applicable | Recruiting | National Science and Technology Council, Taiwan | 50 | 2025-03-01 | 2026-02-27 |
| Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects Pharmacokinetic profiles of Selegiline TDS and EMSAM - MDD | Completed | Corium Innovations, Inc. | 12 | 2025-02-10 | 2026-02-25 | |
| Psilocybin rTMS for Treatment Resistant Depression Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin - Treatment Resistant Depression, MDD | Phase 2 | Recruiting | University of Texas at Austin | 100 | 2025-01-10 | 2025-11-26 |
| At-Home tDCS as Maintenance Therapy tDCS - MDD, Severe Depression | Not applicable | Recruiting | Technical University of Munich | 30 | 2024-10-01 | 2025-12-08 |
| Theta Burst Stimulation for Refractory Depression in Autism Spectrum Disorder Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham - ASD, Autism Spectrum Disorder | Not applicable | Completed | Children's Hospital Medical Center, Cincinnati | 20 | 2024-09-16 | 2026-10-23 |
| Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry Ampa One TMS System - Major Depressive Disorder, MDD | Enrolling by invitation | Biomedical Discoveries and Neuroscientific Foundations LLC | 5000 | 2024-06-27 | 2024-07-22 | |
| Sensation Seeking and TMS Response in TRD Transcranial Magnetic Stimulation (TMS) - MDD, Severe Depression | Recruiting | Technical University of Munich | 100 | 2024-05-02 | 2026-10-22 | |
| Cancer Related Major Depression Treated With a Single Dose of Psilocybin psilocybin 25 mg sod, psilocybin 1 mg sod - MDD | Phase 2 | Recruiting | Section for Affective Disorders; Northern Stockholm Psychiatry | 100 | 2024-04-19 | 2026-04-13 |
| pBFS Guided rTMS Over Different Targets for Treatment-Resistant Depression active rTMS stimulating - Major Depressive Disorder, Treatment Resistant Depression | Not applicable | Unknown | Changping Laboratory | 75 | 2024-02-20 | 2024-02-13 |
| Resonant Frequency rTMS: A Novel Approach to Target Circuit Modulation in Major Depressive Disorder Transcranial Magnetic Stimulation - MDD, Depression | Not applicable | Enrolling by invitation | University of California, Los Angeles | 84 | 2024-02-12 | 2026-09-24 |
| Stress, Inflammation and Neuroimaging in Major Depressive Disorder as Compared to Premenstrual Dysphoric Disorder MDD, PMDD | Recruiting | University Hospital Tuebingen | 75 | 2024-01-04 | 2026-04-07 | |
| Take-home Functional Electrical Stimulation for MDD Functional Electrical Stimulation (FES), Sham FES - MDD | Not applicable | Active not recruiting | Unity Health Toronto | 20 | 2023-12-04 | 2026-06-03 |
| rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFS active rTMS - MDD, Major Depressive Disorder | Not applicable | Unknown | Changping Laboratory | 100 | 2023-11-06 | 2024-02-06 |
Showing 20 of 54. Sign in to see all of them.
Depressive Disorder, Major (26) · Depression (14) · Depressive Disorder, Treatment-Resistant (7) · Anxiety Disorders (4) · Generalized Anxiety Disorder (2) · Neoplasms (2) · Schizophrenia (2) · Stress Disorders, Post-Traumatic (2) · Suicide (2) · Anhedonia (1) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Bipolar Disorder (1) · Cognitive Dysfunction (1) · Inflammation (1)
Mental Disorders (30) · Mood Disorders (29) · Depressive Disorder (28) · Behavior (16) · Behavioral Symptoms (15) · Nervous System Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Schizophrenia Spectrum and Other Psychotic Disorders (2) · Self-Injurious Behavior (2) · Stress Disorders, Traumatic (2) · Trauma and Stressor Related Disorders (2) · Bipolar and Related Disorders (1) · Child Development Disorders, Pervasive (1) · Cognition Disorders (1) · Dyssomnias (1)
Transcranial Magnetic Stimulation (6) · Psilocybin (2) · Transcranial Direct Current Stimulation (2) · Biological Evolution (1) · Bupropion (1) · Cholecalciferol (1) · Citalopram (1) · Dextromethorphan (1) · Eicosapentaenoic Acid (1) · Escitalopram (1) · Fatty Acids, Omega-3 (1) · Genetic Testing (1) · N,N-Dimethyltryptamine (1) · Population Groups (1) · Relaxation Therapy (1)
Changping Laboratory (5) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (3) · AstraZeneca (2) · NYU Langone Health (2) · Stanford University (2) · Technical University of Munich (2) · Unity Health Toronto (2) · University of California, San Francisco (2) · University of North Carolina, Chapel Hill (2) · University of Pennsylvania (2) · Actinogen Medical (1) · Ain Shams University (1) · Autobahn Therapeutics, Inc. (1) · Biomedical Discoveries and Neuroscientific Foundations LLC (1) · Central South University (1)
United States (27) · China (7) · Germany (4) · Bangladesh (3) · Australia (2) · Israel (2) · Italy (2) · Brazil (1) · Canada (1) · Egypt (1) · Estonia (1) · France (1) · Malaysia (1) · Poland (1) · Puerto Rico (1)
Hesheng Liu, Ph.D. (4) · Patricia Arean, Ph.D. (2) · Andreas Fallgatter, Prof. Dr. (1) · Andrew . J Cutler, MD (1) · Angelo Sambunaris, MD (1) · Anupama Kumar (1) · Brian P. Brennan, M.D. (1) · Brooke Hollister, Ph.D. (1) · David Rubinow, MD (1) · Dr. Gino Montagnani (1) · Dr. Mauro Carta (1) · Dr. Raffaele Sabia (1) · Eleanor Cole, PhD (1) · Flavio Frohlich, PhD (1)
PMID 16173961, PMID 20679620, PMID 22084369, PMID 24297868, PMID 25116372, PMID 25514064, PMID 30093372, PMID 30123324, PMID 33031046, PMID 34894307, PMID 35404830, PMID 35499104, PMID 38437873, PMID 38810968, PMID 40319334, PMID 41367968, PMID 41952163, PMID 42721198
2023 (1), R01MH101547 (1), R01MH130539 (1), R01MH135293 (1), R33MH135428 (1), R61MH128492 (1)